Inside Pharma's Revenue Engine: The Gross-to-Net Reckoning

Inside Pharma's Revenue Engine: The Gross-to-Net Reckoning

Pharmaceutical Executive (independent trade outlet)
Pharmaceutical Executive (independent trade outlet)Apr 17, 2026

Key Takeaways

  • GTN (gross-to-net) complexity rising due to opaque PBM contracts.
  • Medicaid exits increase net revenue volatility for drug makers.
  • Coordination of benefits failures cause significant rebate leakage.
  • AI tools needed to close data gaps in pricing visibility.
  • DTC channel pressures strain legacy revenue management systems.

Pulse Analysis

The pharmaceutical industry’s revenue engine is under unprecedented pressure as gross‑to‑net calculations become more intricate. Traditional pricing models, once anchored by stable rebate contracts and clear payer pathways, now contend with a maze of pharmacy‑benefit‑manager (PBM) opacity, fluctuating Medicaid participation, and fragmented coordination of benefits. These forces compress net prices, inflate administrative overhead, and create unpredictable cash flows that can destabilize product profitability, especially for high‑cost specialty therapies.

Compounding the GTN challenge, direct‑to‑consumer (DTC) marketing and emerging distribution channels introduce downstream data gaps that obscure real‑time pricing signals. Without accurate, end‑to‑end visibility, manufacturers struggle to reconcile gross sales with net receipts, leading to “ghost claims” and missed rebate opportunities. The Model N survey underscores that AI and advanced analytics are no longer optional; they are essential for harmonizing disparate data sources, automating rebate eligibility checks, and forecasting net revenue under volatile market conditions.

For executives, the takeaway is clear: investing in next‑generation revenue‑management platforms is a strategic imperative. Leveraging AI to streamline GTN processes can reduce leakage, improve margin protection, and support more agile launch sequencing. As Medicare drug‑price negotiations intensify and MFN agreements demand greater transparency, firms that master GTN complexity will secure a competitive edge, ensuring sustainable growth in an increasingly regulated and price‑sensitive landscape.

Inside Pharma's Revenue Engine: The Gross-to-Net Reckoning

Comments

Want to join the conversation?